Application of cycloastragenol in preparing medicines for treating or preventing Alzheimer's disease

A technology for Alzheimer's disease and cycloastragenol, which is applied in the field of medicine to achieve good therapeutic effects, inhibit inflammation, and reduce deposition

CN110974837APending Publication Date: 2020-04-10潘晓东
1 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2020-04-10

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention provides an application of cycloastragenol in preparing medicines for treating or preventing Alzheimer's disease. Cycloastragenol can promote elimination of key pathological amyloid protein (Abeta) deposition in a brain suffered from Alzheimer's disease and inhibit inflammatory reactions of microglia cells, so that deposition of aging-related substances in the brain is obviously reduced, and aging is resisted. Cycloastragenol can improve glucose metabolism capacity in brain tissues, and has good protection and treatment effects on damage of learning and memory capabilities and behavioral movement capacity caused by Abeta deposition. The features make cycloastragalol suitable for being used in prevention and treatment of Alzheimer's disease, and a solution is providedfor long-troubled treatment of Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine, and relates to a new medicinal application of cycloastragenol, in particular to the application of cycloastragenol in the preparation of drugs for treating Alzheimer's disease. Cycloastragenol can promote the removal of key pathological amyloid (Aβ) deposits in the brain of Alzheimer's disease, inhibit the inflammatory response of microglial cells, significantly reduce the deposition of aging-related substances in the brain, anti-aging, and improve brain tissue. The ability to metabolize glucose has good protective and therapeutic effects on learning, memory, and behavioral motor ability damage caused by Aβ deposition, so it can be used to prepare drugs for preventing or treating Alzheimer's disease. Background technique

[0002] At present, the core hypothesis of Alzheimer's disease (AD), Aβ, has been developed, and the theory of abnormal immune inflammation has become the mainstream mechanism ...

Examples

Embodiment Construction

[0035] The present invention will be further described below in combination with specific embodiments, so that those skilled in the art can better understand the present invention, but the present invention is not limited thereby.

[0036] Pharmacological experimental data of cycloastragenol in the treatment of Alzheimer's disease

[0037] Experiment 1: Evaluation of cycloastragenol on the phagocytosis of microglia

[0038] Experimental materials: BV-2 cells are a mouse microglial cell line with the functions and basic characteristics of primary microglial cells. Fetal bovine serum and high glucose medium containing 0.25% trypsin EDTA, penicillin and streptomycin were used for cultivation. Nile red microglobulin, freeze-dried powder Aβ1-42 and Hilyte555-Aβ1-42 were purchased from Anaspec. The CCK8 reagent for detecting cell activity was purchased from Hyclone Company.

[0039] experimental method:

[0040] 1-1 The optimal concentration of cycloastragenol to BV2 cells was d...